Atrium Therapeutics, Inc. announced in a statement published August 20, 2026, that it awarded inducement grants to a newly hired non-executive individual. The awards were issued under the Company's 2026 Employment Inducement Incentive Award Plan as a material inducement for employment.
The individual received non-qualified stock options to purchase 11,000 shares of the Company's common stock. These options have an exercise price of $13.48 per share, which was the closing price of the Company's common stock on the grant date. Twenty-five percent of these options will vest on the first anniversary of the grant date, with the remainder vesting in 36 monthly installments thereafter, contingent upon continued service.
Additionally, the employee was awarded restricted stock units for an aggregate of 5,500 shares of common stock. Twenty-five percent of these units are scheduled to vest on the first anniversary of the grant date, while the rest will vest in three equal annual installments, subject to continued service.
The awards were approved by the Human Capital Management Committee of the Company's Board of Directors, which consists of independent directors, in accordance with Nasdaq Listing Rule 5635(c)(4). Atrium Therapeutics is currently developing RNA therapeutics to target cardiomyopathies, including its ATR 1072 program for PRKAG2 syndrome.
